San Miguel Jesus

Chronic graft‐versus‐host disease of the kidney in patients with allogenic hematopoietic stem cell transplant

Fraile Pilar, Vazquez Lourdes, Caballero Dolores, 2013 .

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Hartmut Goldschmidt, Mario Boccadoro, David Irwin, 2005, The New England journal of medicine.

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

A. Krishnan, J. Goldberg, J. Infante, 2021, The Lancet.

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective

H. Einsele, P. Moreau, J. San-Miguel, 2016, Advances in Therapy.

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.

L. Staudt, W. Chan, W. Wilson, 2022, Blood.

Comparison of efficacy from two different dosing regimens of bortezomib: an exposure–response analysis

M. Dimopoulos, J. San-Miguel, M. Mateos, 2020, British journal of haematology.

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.

A. Órfão, N. Puig, A. Oriol, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

D. Esseltine, P. Ganly, P. Richardson, 2017, Blood.